By William Blum and
82 pages, 13 illustrations
$25.00 (Our delivery cost is a flat fee of $9.00 so the more you order the better!)
This last year has seen the approval of the first targeted treatments for acute myeloid leukemia (AML) – following decades with no new developments and a poor prognosis for most patients with the disease. The new drugs reflect the remarkable progress that has been made in our understanding of the pathophysiology of AML and its underlying cytogenetic and molecular abnormalities – which differ not only between patients but also within a patient over time and with treatment.
Fast Facts: Acute Myeloid Leukemia provides a comprehensive yet concise foundation for understanding AML: from basic epidemiology, diagnosis, classification and the current ‘standard’ treatment, through to recent advances in our understanding of the cytogenetic and molecular underpinnings of the disease, such as the IDH2 mutation, and the future for tailored therapy. It will be useful to primary care providers, medical students, specialist nurses, junior doctors and allied healthcare professionals who want to develop a thorough grounding in our evolving understanding of AML and its treatment.
• Epidemiology, pathophysiology and etiology
• Supportive care
• Prognosis and monitoring
• Emerging treatments
• Useful resources
MD Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine; Director, Acute Leukemia Program, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA
MD, DM Associate Director, Professor and Head, Department of Haematology, Christian Medical College, Vellore, India
Are you a healthcare professional?
Have you taken the FastTest for this title?
Thank you for your feedback
Feel free to leave a comment for the authors below.
If you haven't already, don't forget to take the FastTest for this title.
Good health decisions